Jiyoun Choi
Research Subjects
Jiyoun Choi has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Heon Yoo
Neuro-Oncology Clinic, National Cancer Center, Goyang, Korea
4 shared publications - Ho-Shin Gwak
National Cancer Center 5 Neuro-oncology clinic Goyang, Republic of Korea
4 shared publications - Ju-Hwang Park
CGT center, CellabMED Inc., Seoul, Republic of Korea
4 shared publications - Kiwan Kim
R&D center, CellabMED Inc., Seoul, Republic of Korea
4 shared publications - Kyu-Chang Wang
Neuro-oncology Clinic, Center for Rare Cancers, National Cancer Center, Goyang, Republic of Korea
4 shared publications - Nayoung Han
Department of Pathology, National Cancer Center, Goyang, Korea
4 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Data from Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics
Purpose:This single-center, open-label, phase I trial evaluated the safety and tolerability of chimeric antigen receptor (CAR) T cells targeting interleukin 13 receptor α2 (IL13Rα2) in patients with malignant gliomas. Patients and Methods:Adults with World Health Organization grade 3 to 4 gliomas, recurrent after standard treatment and expressing IL13Rα2 (confirmed by immunohistochemistry), received a single intravenous infusion of autologous CAR T cells. Primary objectives were to measure the maximum tolerated dose (MTD) and recommended phase II dose. Secondary objectives included assessment of pharmacokinetics, objective response rate, progression-free survival (PFS), and overall survival (OS). Results:Ten patients were sequentially assigned to 3 dosing cohorts (1 × 107, 3 × 107, and 1 × 108 cells/kg). The MTD was not reached, as no dose-limiting toxicities were observed, and all adverse events (AE) were grade ≤3 without irreversible sequelae. The most common treatment-related AE were pyrexia (70%) and elevated transaminase (70%). CAR T-cell levels in blood reached peak concentrations at a median of 7 days (range, 3–14), and the transgene was detected in cerebrospinal fluid from 5 of 6 patients treated at the higher 2 doses. Nine patients were evaluable for survival analysis, among whom 6 were available for response assessment at 3 months; best response was stable disease in 3 cases. The median PFS was 2.6 months [95% confidence interval (CI), 0.95–5.75], and the median OS was 10.9 months (95% CI, 8.2–26.6). Conclusions:Intravenous IL13Rα2-targeted CAR T therapy was well tolerated and demonstrated preliminary safety. Further studies are warranted to optimize dosing and preconditioning regimens and identify exploratory biomarkers for efficacy evaluation.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics
Purpose:This single-center, open-label, phase I trial evaluated the safety and tolerability of chimeric antigen receptor (CAR) T cells targeting interleukin 13 receptor α2 (IL13Rα2) in patients with malignant gliomas. Patients and Methods:Adults with World Health Organization grade 3 to 4 gliomas, recurrent after standard treatment and expressing IL13Rα2 (confirmed by immunohistochemistry), received a single intravenous infusion of autologous CAR T cells. Primary objectives were to measure the maximum tolerated dose (MTD) and recommended phase II dose. Secondary objectives included assessment of pharmacokinetics, objective response rate, progression-free survival (PFS), and overall survival (OS). Results:Ten patients were sequentially assigned to 3 dosing cohorts (1 × 107, 3 × 107, and 1 × 108 cells/kg). The MTD was not reached, as no dose-limiting toxicities were observed, and all adverse events (AE) were grade ≤3 without irreversible sequelae. The most common treatment-related AE were pyrexia (70%) and elevated transaminase (70%). CAR T-cell levels in blood reached peak concentrations at a median of 7 days (range, 3–14), and the transgene was detected in cerebrospinal fluid from 5 of 6 patients treated at the higher 2 doses. Nine patients were evaluable for survival analysis, among whom 6 were available for response assessment at 3 months; best response was stable disease in 3 cases. The median PFS was 2.6 months [95% confidence interval (CI), 0.95–5.75], and the median OS was 10.9 months (95% CI, 8.2–26.6). Conclusions:Intravenous IL13Rα2-targeted CAR T therapy was well tolerated and demonstrated preliminary safety. Further studies are warranted to optimize dosing and preconditioning regimens and identify exploratory biomarkers for efficacy evaluation.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table1 from Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics
S1. Eligibility criteria S2.Representativeness of study participants S3.Patients’characteristics S4. Release criteria S5. Immunophenotypic composition S6. Individual CAR-T transgene copy number S7. pharmacokinetic parameters in blood S8. Individual patient serum cytokine S9. Median peak time and peak fold change of serum cytokines S10.Individual patient CSF cytokine levels S11. Baseline tumor size and longitudinal radiographic changes
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table1 from Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics
S1. Eligibility criteria S2.Representativeness of study participants S3.Patients’characteristics S4. Release criteria S5. Immunophenotypic composition S6. Individual CAR-T transgene copy number S7. pharmacokinetic parameters in blood S8. Individual patient serum cytokine S9. Median peak time and peak fold change of serum cytokines S10.Individual patient CSF cytokine levels S11. Baseline tumor size and longitudinal radiographic changes
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures1 from Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics
S1. Characteristics of infused YYB-103 S2. MRI of A3-03 S3. Pheripheral blood lymphocyte level S4. Serum testosterone level S5. In vivo expansion profile of YYB-103 in blood and CSF S6. Serum and CSF cytokine profiles S7. Correlation between pheripheral blood CAR-T expansion and longitudinal radiographic changes S8. MRI of A1-03
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures1 from Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics
S1. Characteristics of infused YYB-103 S2. MRI of A3-03 S3. Pheripheral blood lymphocyte level S4. Serum testosterone level S5. In vivo expansion profile of YYB-103 in blood and CSF S6. Serum and CSF cytokine profiles S7. Correlation between pheripheral blood CAR-T expansion and longitudinal radiographic changes S8. MRI of A1-03
- 4 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4656-4667
Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics
Purpose: This single-center, open-label, phase I trial evaluated the safety and tolerability of chimeric antigen receptor (CAR) T cells targeting interleukin 13 receptor α2 (IL13Rα2) in patients with malignant gliomas. Patients and Methods: Adults with World Health Organization grade 3 to 4 gliomas, recurrent after standard treatment and expressing IL13Rα2 (confirmed by immunohistochemistry), received a single intravenous infusion of autologous CAR T cells. Primary objectives were to measure the maximum tolerated dose (MTD) and recommended phase II dose. Secondary objectives included assessment of pharmacokinetics, objective response rate, progression-free survival (PFS), and overall survival (OS). Results: Ten patients were sequentially assigned to 3 dosing cohorts (1 × 107, 3 × 107, and 1 × 108 cells/kg). The MTD was not reached, as no dose-limiting toxicities were observed, and all adverse events (AE) were grade ≤3 without irreversible sequelae. The most common treatment-related AE were pyrexia (70%) and elevated transaminase (70%). CAR T-cell levels in blood reached peak concentrations at a median of 7 days (range, 3–14), and the transgene was detected in cerebrospinal fluid from 5 of 6 patients treated at the higher 2 doses. Nine patients were evaluable for survival analysis, among whom 6 were available for response assessment at 3 months; best response was stable disease in 3 cases. The median PFS was 2.6 months [95% confidence interval (CI), 0.95–5.75], and the median OS was 10.9 months (95% CI, 8.2–26.6). Conclusions: Intravenous IL13Rα2-targeted CAR T therapy was well tolerated and demonstrated preliminary safety. Further studies are warranted to optimize dosing and preconditioning regimens and identify exploratory biomarkers for efficacy evaluation.
- 4 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4656-4667
Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics
Purpose: This single-center, open-label, phase I trial evaluated the safety and tolerability of chimeric antigen receptor (CAR) T cells targeting interleukin 13 receptor α2 (IL13Rα2) in patients with malignant gliomas. Patients and Methods: Adults with World Health Organization grade 3 to 4 gliomas, recurrent after standard treatment and expressing IL13Rα2 (confirmed by immunohistochemistry), received a single intravenous infusion of autologous CAR T cells. Primary objectives were to measure the maximum tolerated dose (MTD) and recommended phase II dose. Secondary objectives included assessment of pharmacokinetics, objective response rate, progression-free survival (PFS), and overall survival (OS). Results: Ten patients were sequentially assigned to 3 dosing cohorts (1 × 107, 3 × 107, and 1 × 108 cells/kg). The MTD was not reached, as no dose-limiting toxicities were observed, and all adverse events (AE) were grade ≤3 without irreversible sequelae. The most common treatment-related AE were pyrexia (70%) and elevated transaminase (70%). CAR T-cell levels in blood reached peak concentrations at a median of 7 days (range, 3–14), and the transgene was detected in cerebrospinal fluid from 5 of 6 patients treated at the higher 2 doses. Nine patients were evaluable for survival analysis, among whom 6 were available for response assessment at 3 months; best response was stable disease in 3 cases. The median PFS was 2.6 months [95% confidence interval (CI), 0.95–5.75], and the median OS was 10.9 months (95% CI, 8.2–26.6). Conclusions: Intravenous IL13Rα2-targeted CAR T therapy was well tolerated and demonstrated preliminary safety. Further studies are warranted to optimize dosing and preconditioning regimens and identify exploratory biomarkers for efficacy evaluation.